HIV lipodystrophy is a heterogeneous syndrome, which has yet to be objectively defined,
comprising peripheral lipoatrophy, central fat accumulation and lipomata, along with …

In developed countries, the availability of highly active antiretroviral therapy (HAART) has
contributed to a dramatic decrease in mortality and opportunistic infections associated with …

Approximately two years after the introduction of highly active antiretroviral therapy for the
treatment of HIV infection, body shape changes and metabolic abnormalities were …

Background Lipodystrophy (peripheral lipoatrophy, central fat accumulation, and
lipomatosis) is a common and disfiguring problem in adult patients with HIV-1 infection on …

Lipodystrophy (LD) is a common adverse effect of HIV treatment with highly active
antiretroviral therapy, which comprises morphological and metabolic changes. The …

Lipodystrophy is a common alteration in HIV 1-infected patients under anti-retroviral
treatment. This syndrome is usually associated with peripheral lipoatrophy, central adiposity …

Potent antiretroviral agents markedly suppress HIV and have dramatically improved the
clinical course, prognosis, and survival of HIV-infected patients. Unfortunately, highly active …

Objective To establish the prevalence, severity and factors associated with the HIV
lipodystrophy syndrome. Methods Cross‐sectional study of lipodystrophy conducted in high …

A subset of HIV-1-infected patients undergoing antiretroviral treatment develops a
lipodystrophy syndrome. It is characterized by loss of peripheral subcutaneous adipose …

Objective To provide population-based estimates of the prevalence of lipodystrophy
syndrome and constituent symptoms and to identify correlates of prevalent symptomology …